Market Access News | pharmaphorum

News

Indivior stung by fraud charges over US marketing

Shares in UK drugmaker Indivior have gone into freefall after it was charged by the US Department of Justice for fraudulently marketing its opioid addiction treatment.

News

Drug middlemen point finger at pharma in US pricing debate

The so-called ‘middlemen’ in the US pharma supply chain have blamed big pharma for skyrocketing drug prices in the country, as the Senate Finance Committee grilled them over the deals they strik

News

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast c...

The European Commission has approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of germline BRCA-mutated HER2-negative advanced breast cancer – making it the first drug app

News

At long last, Amgen/UCB score FDA okay for Evenity

Amgen and UCB finally have FDA approval for osteoporosis drug Evenity, two years after it was turned down by the regulator because of safety concerns.

News

Zogenix slumps after FDA refuses epilepsy drug file

Zogenix’s only drug candidate is facing a long delay after the FDA refused to accept its marketing application, asking for toxicology data.

News

Group of young multiracial woman with red ribbons in hands are struggling against HIV/AIDS. AIDS awareness concept.

ViiV hopes for blockbuster with HIV drug combo approval

The FDA has approved ViiV’s Dovato, a single-tablet, two drug HIV drug regimen of dolutegravir and lamivudine for treatment-naïve patients, making it the only company to have such a drug on

Indivior stung by fraud charges over US marketing

Drug middlemen point finger at pharma in US pricing debate

AZ and MSD’s Lynparza gets EU nod for hard-to-treat breast c...

At long last, Amgen/UCB score FDA okay for Evenity

Zogenix slumps after FDA refuses epilepsy drug file

ViiV hopes for blockbuster with HIV drug combo approval

Tarsus places $800m wager on Alkeus' Stargardt therapy

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks